Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.
Parada-Márquez JF et al.
Frontiers in Pharmacology, 2023
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
PharmVar GeneFocus: CYP2B6.
Desta Z et al.
Clinical Pharmacology and Therapeutics, 2021
Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.
Zakerska-Banaszak O et al.
Scientific Reports, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Polymorphisms and haplotypes of the CYP2B6 detoxification gene in the predisposition of Acute Myeloid Leukemia (AML) and induction of its cytogenetic abnormalities.
Daraki A et al.
Cancer Genetics, 2016
Insights into CYP2B6-mediated drug-drug interactions.
Hedrich WD et al.
Acta Pharmaceutica Sinica. B, 2016
Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children.
Franca R et al.
International Journal of Molecular Sciences, 2015
MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing.
Mort M et al.
Genome Biology, 2014
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O et al.
Addiction Biology, 2013
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J et al.
Pharmacogenomics, 2012
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
Hofmann MH et al.
The Journal of Pharmacology and Experimental Therapeutics, 2008
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ et al.
Pharmacogenetics and Genomics, 2007
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
David SP et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2007
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Rotger M et al.
Clinical Pharmacology and Therapeutics, 2007
Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.
Guan S et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2006
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.
Mehlotra RK et al.
European Journal of Clinical Pharmacology, 2006
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Klein K et al.
Pharmacogenetics and Genomics, 2005
Cancer pharmacogenomics: achievements in basic research.
Nakajima M et al.
International Journal of Clinical Oncology, 2005
Haplotype structure and allele frequencies of CYP2B6 in a Korean population.
Cho JY et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2004
Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping.
Jacob RM et al.
Clinical Chemistry, 2004
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM et al.
Pharmacogenetics, 2004
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J et al.
Pharmacogenetics, 2003
Functional characterization of cytochrome P450 2B6 allelic variants.
Jinno H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.
Lang T et al.
Pharmacogenetics, 2001
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S et al.
The Pharmacogenomics Journal, 0